PharmaCyte Biotech, Inc. — Form SCHEDULE 13D/A
Filed November 20, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
PharmaCyte Biotech filed an amended Schedule 13D/A on November 20, 2026, disclosing a beneficial ownership position in Q/C Technologies, Inc. (a diagnostic substances company). The filing document itself contains no specific dollar amounts, share counts, ownership percentages, or details of what changed from the original filing—only administrative header information is provided in this extract.
Why this rating
Schedule 13D amendments are routine disclosure updates. Without concrete ownership %, dollar amounts, or strategic detail visible here, cannot assess materiality. Relative to PharmaCyte's $6.3M market cap, would need specifics to judge impact.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.